Currently undergoing clinical trials, the drug saracatinib, which was originally developed for cancer, is being repurposed as a treatment for Alzheimer’s. Animal testing at the Yale University School of Medicine showed a decrease in memory loss and reversal of brain damage caused by the mouse model of the disease. After obtaining the drug from AstraZeneca, researchers were able to begin Phase II clinical trials, which usually take 10 years to prepare for, within 18 months.


National Institute of Health
See article in Annals of Neurology here